0000000000140815

AUTHOR

Jörn M Schattenberg

showing 3 related works from this author

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

2020

© 2020 The Author(s).

Liver CirrhosisPROGNOSISCirrhosisSCORING SYSTEM[SDV]Life Sciences [q-bio]PROGRESSIONDiseaseBiomarker Cirrhosis NAFLD NASHSTEATOHEPATITISDEFINITIONSCohort Studies0302 clinical medicineNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasePharmacology (medical)030212 general & internal medicineLongitudinal StudiesRegistriesComputingMilieux_MISCELLANEOUSmedia_commonPharmacology. TherapyFatty liverLiver NeoplasmsNASHGeneral Medicine3. Good healthCirrhosisLiver317 PharmacyCohort0305 other medical scienceCohort studymedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIAGeriatrikQUESTIONNAIRENAFLD; NASH; Cirrhosis; Biomarker610 Medicine & health03 medical and health sciencesNAFLDmedicineSTEATOSISmedia_common.cataloged_instanceHumansALGORITHMEuropean unionIntensive care medicine030505 public healthbusiness.industryCONSUMPTIONBiomarkerSTAGING SYSTEMmedicine.diseaseDiabetes Mellitus Type 2Geriatrics3121 General medicine internal medicine and other clinical medicine3111 BiomedicineHuman medicineSteatohepatitisbusinessBiomarker; Cirrhosis; NAFLD; NASH
researchProduct

Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease

2020

AbstractObesity-associated inflammation is a key player in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, the exact mechanisms remain incompletely understood. Here we demonstrate that macrophage scavenger receptor 1 (MSR1, CD204) expression is associated with the occurrence of hepatic lipid-laden foamy macrophages and correlates with the degree of steatosis and steatohepatitis in a cohort of 170 NAFLD patients. Mice lacking Msr1 are protected against high fat-cholesterol diet (HFD)-induced metabolic disorder, showing fewer hepatic lipid-laden foamy macrophages, less hepatic inflammation, improved dyslipidemia and glucose tolerance, while showing a change in hepatic …

0303 health sciencesmedicine.medical_specialtyLipopolysaccharidebusiness.industryFatty liverInflammationmedicine.disease3. Good healthMSR1Pathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologychemistryFibrosisInternal medicineMedicine030211 gastroenterology & hepatologySteatohepatitismedicine.symptomSteatosisbusiness030304 developmental biology
researchProduct

Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection

2020

Data on the prevalence of resistance-associated substitutions (RASs) and their implications for treatment with direct-acting antivirals (DAAs) are sparse in European patients with HCV genotype 4. This study investigated RASs before and after DAA failure in different genotype 4 subtypes and evaluated retreatment efficacies. Samples of 195 genotype 4-infected patients were collected in the European Resistance Database and investigated for NS3, NS5A and NS5B RASs. Retreatment efficacies in DAA failure patients were analysed retrospectively. After NS5A inhibitor (NS5Ai) failure, subtype 4r was frequent (30%) compared to DAA-naive patients (5%) and the number of NS5A RASs was significantly highe…

medicine.medical_specialtyGenotypeHepatitis C virusMedizinHCV genotype 4HepacivirusViral Nonstructural Proteinsmedicine.disease_causeGastroenterologyAntiviral AgentsVirus03 medical and health scienceschemistry.chemical_compound0302 clinical medicineResistance-associated substitutionsChronic hepatitisMembrane interactionVirologyInternal medicineGenotypeDrug Resistance ViralmedicineHumansIn patient030212 general & internal medicineTreatment FailureNS5ANS5BRetrospective Studiesddc:616Hepatologybusiness.industryHepatitis C virusvirus diseasesHepatitis C Chronicdigestive system diseasesInfectious DiseaseschemistryRetreatmentDAA failure030211 gastroenterology & hepatologybusiness
researchProduct